Daiichi and Merck's I-Dxd lung cancer study faces partial hold due to deaths

The FDA placed a partial hold on Daiichi Sankyo and Merck’s Phase 3 study of a lung cancer drug after the companies paused enrollment for what they called a "higher than anticipated incidence" of deaths ...